Genomic Health Inc.Find Ratings Reports
GENOMIC HEALTH INC's gross profit margin for the fourth quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. GENOMIC HEALTH INC is extremely liquid. Currently, the Quick Ratio is 4.07 which clearly shows the ability to cover any short-term cash needs. GHDX managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 20.61% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||87.46||82.74|
|Net Income ($mil)||1.88||1.35|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||129.58||96.99|
|Total Assets ($mil)||231.62||201.11|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||87.86||86.26|
|Return on Assets||-1.66||-6.92|
|Return on Equity||-2.04||-8.91|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||34.79||33.83|
|Div / share||0.0||0.0|
|Book value / share||5.41||4.61|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||219822.0||123477.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 5.82 indicates a significant premium versus the S&P 500 average of 3.27 and a significant discount versus the industry average of 20.74. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, GENOMIC HEALTH INC proves to trade at a discount to investment alternatives within the industry.
|GHDX NM||Peers 46.41||GHDX NA||Peers 24.87|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
GHDX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|GHDX 50.42||Peers 17.63||GHDX NA||Peers 0.37|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
GHDX is trading at a significant premium to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|GHDX 5.82||Peers 20.74||GHDX 73.18||Peers 0.49|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
GHDX is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
GHDX is expected to have an earnings growth rate that significantly exceeds its peers.
|GHDX 3.22||Peers 83.14||GHDX 3.92||Peers 469.60|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
GHDX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
GHDX significantly trails its peers on the basis of sales growth